S. Vermeire

发表

Mesenteric SParIng versus extensive mesentereCtomY in primary ileocolic resection for ileocaecal Crohn’s disease (SPICY): study protocol for randomized controlled trial

A. Spinelli, M. Duijvestein, B. Koot, 2022, BJS open.

Community types of the human gut virome are associated with endoscopic outcome in ulcerative colitis

J. Raes, G. Falony, J. Matthijnssens, 2022, medRxiv.

OP34 Efficacy and safety of advanced induction and maintenance therapies in patients with moderately to severely active Ulcerative Colitis: An indirect treatment comparison using Bayesian network meta-analysis

P. Higgins, R. Panaccione, S. Danese, 2022, Journal of Crohn's and Colitis.

Upadacitinib Therapy Reduces Ulcerative Colitis Symptoms as Early as Day 1.

R. Panaccione, S. Danese, S. Schreiber, 2022, Gastroenterology & hepatology.

DOP41 Efficacy and safety of extended induction treatment with upadacitinib 45 mg once daily followed by maintenance upadacitinib 15 or 30 mg once daily in patients with moderately to severely active Ulcerative Colitis

P. Higgins, R. Panaccione, S. Danese, 2022, Journal of Crohn's and Colitis.

P370 Maintenance of health-related quality of life improvements with upadacitinib treatment among patients with moderately to severely active ulcerative colitis: results from, 52-week phase, 3 study U ACHIEVE maintenance

J. Lindsay, J. Panés, Y. Sanchez Gonzalez, 2022, Journal of Crohn's and Colitis.

Clinical and scientific aspects related to biosimilars in inflammatory bowel diseases (IBD): position document of the Belgian IBD Research & Development Group (BIRD).

O. Dewit, D. Franchimont, E. Louis, 2015, Acta gastro-enterologica Belgica.

OP03 Standardized faecal microbiota transplantation with microbiome-guided donor selection in active UC patients: A randomized, placebo-controlled intervention study

J. Raes, G. Falony, D. Franchimont, 2022, Journal of Crohn's and Colitis.

P024 Repeated cycles of DSS inducing a chronically relapsing inflammation: A novel model to study fibrosis using in vivo MRI T2 relaxometry

P. Rutgeerts, T. Dresselaers, U. Himmelreich, 2012 .

P517 Re-treatment with filgotinib in patients with Ulcerative Colitis following treatment interruption: Analysis of the SELECTION and SELECTIONLTE studies

G. Rogler, L. Peyrin-Biroulet, M. Faes, 2022, Journal of Crohn's and Colitis.

P576 Real-world effectiveness and safety of risankizumab in patients with moderate-to-severe multi-refractory Crohn’s disease: a Belgian multi-centric cohort study

D. Franchimont, M. Ferrante, J. Sabino, 2022, Journal of Crohn's and Colitis.

P476 Characterization of cardiac conduction abnormalities reported in the phase 3 ELEVATE programme

L. Peyrin-Biroulet, I. Modesto, M. Dubinsky, 2023, Journal of Crohn's & Colitis.

P490 Etrasimod for the treatment of ulcerative colitis: up to 2.5 years of pooled safety data from global clinical trials

L. Peyrin-Biroulet, S. Danese, J. Panés, 2023, Journal of Crohn's and Colitis.

P690 Prolonged benefit of filgotinib in patients with Ulcerative Colitis in SELECTION

A. Sturm, D. Laharie, A. Oortwijn, 2023, Journal of Crohn's and Colitis.

P632 Etrasimod induction therapy in moderately to severely active Crohn’s disease: results from a phase 2, randomised, double-blind substudy

G. D'Haens, L. Peyrin-Biroulet, S. Danese, 2023, Journal of Crohn's and Colitis.

OP40 PRA023 Demonstrated Efficacy and Favorable Safety as Induction Therapy for Moderately to Severely Active UC: Phase 2 ARTEMIS-UC Study Results

L. Peyrin-Biroulet, S. Danese, J. Kierkuś, 2023, Journal of Crohn's and Colitis.